Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Hepatology
Metabolic Dysfunction-Associated Liver Diseases
Questions discussed in this category
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
1 Answer available
22838
Papers discussed in this category
International journal of molecular sciences, 2022 Mar 13
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
Related Topics in Hepatology
General Internal Medicine
Gastroenterology
General Hepatology
Metabolic Dysfunction-Associated Liver Diseases
Rheumatology
Rheumatoid Arthritis
General Rheumatology
JAK Inhibitors
Cirrhosis
Diabetes